Val-Cit-PAB-Exatecan

Item no.	HY-153031-100mg
Manufacturer	MedChem Express
CASRN	2227350-99-2
Amount	100 mg
Quantity options	100 mg 10 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Amino Acid Derivates general
Type	Amino Acid Derivates
Specific against	other
Purity	99.79
Citations	[1]Thomas A, et al. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254-e262.
Smiles	CC(C)[C@H](N)C(N[C@@H](CCCNC(N)=O)C(NC(C=C1)=CC=C1COC(N[C@@H]2C3=C4C(C(N5C4)=CC([C@](O)(C(OC6)=O)CC)=C6C5=O)=NC7=CC(F)=C(C)C(CC2)=C73)=O)=O)=O
Alias	Val-Cit-PAB-DX8951
Shipping Condition	Cool pack
Available
Manufacturer - Type	ADC Related
Manufacturer - Targets	Drug-Linker Conjugates for ADC; Topoisomerase
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	840.90
Product Description	Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Isoform	Camptothecins
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-153031-100mg-safety-datasheet.pdf